Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma

AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Stocks to Buy for the Long Term.

On January 27, Citi modestly cut its price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while leaving its Neutral rating unchanged. The adjustment was part of the firm’s broader Q4 review of the biopharma space. In its note, Citi said expectations across the sector look manageable, with earnings that could come in better than feared, and added that lower policy-related risk could create a more supportive backdrop for the group in 2026.

At the same time, AbbVie faced some disappointing clinical news. According to a January 16 Reuters report, AbbVie and its partner Genmab said their blood cancer drug epcoritamab failed to show a clear survival benefit in a late-stage study. The trial enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma who had already been treated at least once and were not eligible for intensive chemotherapy followed by a stem cell transplant.

While patients on the drug did not live longer in a statistically meaningful way at the time of the analysis, the study did deliver some encouraging signals. The companies said more patients saw their cancer become undetectable, responses lasted longer, and the time before needing another treatment improved. AbbVie and Genmab said they plan to review the data with regulators and share additional results at upcoming medical conferences.

Epcoritamab is already approved in several countries for other lymphoma indications. It is sold as Epkinly in the U.S. and Japan, and as Tepkinly in the European Union.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on discovering, developing, and bringing new medicines to market.

READ NEXT: 13 Companies that Just Started Paying Dividends and 14 High Yield Dividend Stocks with Sustainable Payouts

Disclosure: None.